Pulmonary arterial hypertension: Evaluation and management

Southern Medical Journal

Volumn 100, Issue 4, 2007, Pages 393-399

  LaRaia, Anne V ^a   Waxman, Aaron B ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b PFIZER INC   (United States)

Author keywords

Endothelin; Prostacyclin; Pulmonary hypertension; Pulmonary vascular disease

Indexed keywords

ADENOSINE; AMBRISENTAN; BERAPROST; BOSENTAN; DIGITALIS; DIURETIC AGENT; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; SEROTONIN; SILDENAFIL; SITAXSENTAN; UNIPROST; VASOACTIVE INTESTINAL POLYPEPTIDE; WARFARIN;

ANTICOAGULATION; BONE PAIN; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG INDUCED HEADACHE; FLUSHING; HUMAN; LIVER FUNCTION; NAUSEA; OXYGEN THERAPY; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIAC SURGICAL PROCEDURES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; PULMONARY WEDGE PRESSURE; RECEPTOR, ENDOTHELIN A; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34147148630     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31802f2ff1     Document Type: Review

References (49)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-223.
2. Naeije R, Vachiery JL. Medical therapy of pulmonary hypertension: conventional therapies. Clin Chest Med 2001;22:517-527.
3. Dresdale DT Schultz M, Michtom RJ. Primary pulmonary hypertension, I: clinical and hemodynamic study. Am J Med 1951:11:686-705.
4. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):5S-12S.
5. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352:719-725.
6. Hyduk A, Croft JB, Ayala C, et al. Pulmonary hypertension surveillance: United States, 1980-2002 MMWR Surveill Summ. 2005;54:1-28.
7. Farber HW, Loscalzo J. Pulmonary arterial hypertension N Engl J Med 2004;351:1655-1665.
8. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-1932.
9. Berger M, Haimonwitz A, Van Tosh, A et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985;6:359-365.
10. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739.
11. Yeager ME, Halley GR, Golpon HA, et al. Microsatellite instability of endothelial cell growth and apoptosis within plexiform lesions in primary pulmonary hypertension Circ Res 2001;88:e2-e11.
12. Machado RD, James V, Southwood M, et al. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 2005;111:607-613.
13. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-616.
14. Mark EJ, Patalas ED, Chang HT, et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997;337:602-606.
15. Garcia-Dorado D, Miller DD, Garcia EJ, et al. An epidemic of pulmonary hypertension after toxic rapeseed oil ingestion in Spain. J Am Coll Cardiol 1983;1:1216-1222.
16. Opravil M, Pechere M, Speich R, et al. HIV-associated primary pulmonary hypertension: a case control study. Am J Respir Crit Care Med 1997;155:990-995.
17. Hervé P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-1166.
18. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735-740.
19. Wagenvoort CA. Lung biopsy specimens in the evaluation of pulmonary vascular disease. Chest 1980;77:614-625.
20. Kruger S, Haage P, Hoffmann R, et al. Diagnosis of pulmonary arterial hypertension and pulmonary embolism with magnetic resonance angiography Chest 2001;120:1556-1561.
21. Nikolaou K, Schoenberg SO, Attenberger U, et al. Pulmonary arterial hypertension: diagnosis with fast perfusion MR imaging and high-spacial- resolution MR angiography-preliminary experience. Radiology 2005;236:694-703.
22. Naeije R, Torbicki A. More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J 1995;8:1445-1449.
23. McGoon M. The assessment of pulmonary hypertension. Clin Chest Med 2001;22:493-508.
24. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984;70:657-662.
25. Penning S, Robinson KD, Major CA, et al. A comparison of echocardiography and pulmonary artery catheterization for evaluation of pulmonary artery pressures in pregnant patients with suspected pulmonary hypertension. Am J Obstet Gynecol 2001;184:1568-1570.
26. Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheum 1997;36:239-243.
27. Bossone E, Duong-Wagner TH, Paciocco G, et al. Echocardiographic features of primary pulmonary hypertension. J Am Soc Echocardiogr 1999;12:655-662.
28. Chan KL, Currie PJ, Seward JB, et al. Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. J Am Coll Cardiol 1987;9:549-554.
29. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000;6:453-458.
30. Hinderliter AL, Willis PW IV, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension: primary pulmonary hypertension study group. Circulation 1997;95:1479-1486.
31. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary testing. Am J Respir Crit Care Med 2000;161:487-492.
32. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmaol 2003;41:293-299.
33. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788.
34. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
35. Simmonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: a double-blind randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804.
36. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol ; 2003;41:2119-2125.
37. Olschewski H, Simmonneau G, Galie N, et al. Inhaled iolprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329.
38. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary artery hypertension. N Engl J Med 2005;353:2148-2157.
39. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-249.
40. Langleben D, Brock T, Dixon R, et al. STRIDE 1: effects of the selective ETA receptor antagonist, sitaxsentan sodium, in a patient population with pulmarterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol 2004;44:S80-S84.
41. Business Wire from April 10, 2006, Gilead Sciences, Inc. ARIES-1 Trial. Available at: http://investor.myogen.com/phoenix.zhtml?c= 135160&p= irolnewsArticle&ID=781654&highlight=. Accessed March 1, 2007.
42. Day R, Agyman AS, Segel MJ, et al. Serotonin induces pulmonary artery smooth muscle cell migration. Biochem Pharmacol 2006;71:386-397.
43. Wilkens H, Guth A, König J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-1222.
44. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-587.
45. Rich S, Kaugmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
46. Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997;112:714-721.
47. Rubin LJ, Rich S. Medical management. . In: Rubin L, Rich S, eds. Primary Pulmonary Hypertension. New York, Marcel Dekker, 1997, pp 271-286.
48. Thistlethwaite PA, Jamieson SW. Tricuspid valvular disease in the patient with chronic pulmonary thromboembolic disease. Curr Opin Cardiol 2003;18:111-116.
49. Menzel T, Kramm T, Wagner S, et al. Improvement of tricuspid regurgitation after pulmonary thromboendarterectomy. Ann Thorac Surg 2002;73:756-761.